| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Shah Ebrahim | Q90615321 |
| Paul Dieppe | Q112394452 | ||
| P2093 | author name string | Peter Davey | |
| Christopher Bartlett | |||
| Lesley Doyal | |||
| P2860 | cites work | Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis | Q24655364 |
| Adverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tract | Q28199102 | ||
| Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint | Q30874292 | ||
| Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. | Q33895894 | ||
| Risk of cardiovascular events associated with selective COX-2 inhibitors | Q34087109 | ||
| Age and gender bias in statin trials. | Q34190182 | ||
| Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs | Q34326331 | ||
| The causes and effects of socio-demographic exclusions from clinical trials | Q34561109 | ||
| Exclusion of elderly people from clinical research: a descriptive study of published reports | Q36246865 | ||
| Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications | Q39471536 | ||
| Renal syndromes associated with nonsteroidal antiinflammatory drugs | Q40168640 | ||
| Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure | Q42277500 | ||
| Using patient-identifiable data for observational research and audit | Q42768927 | ||
| Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain | Q44232373 | ||
| Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. | Q50988080 | ||
| Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. | Q52864626 | ||
| Salicylates and renal function in rheumatoid arthritis | Q66684915 | ||
| Nonsteroidal anti-inflammatory drugs and renal disease--still unsettled | Q70210559 | ||
| Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group | Q70844927 | ||
| Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts | Q71215736 | ||
| Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis | Q72526711 | ||
| Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States | Q74552365 | ||
| The impracticable nature of consent for research use of linked administrative health records | Q77102591 | ||
| Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center | Q77824770 | ||
| A comparison of the views of rheumatologists, general practitioners and patients on the treatment of osteoarthritis | Q78328801 | ||
| P433 | issue | 7456 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 31-34 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs | |
| P478 | volume | 329 |
| Q35556027 | A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs |
| Q40446574 | Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria. |
| Q42386632 | Balancing benefits and harms in health care: ethical dimension was not discussed in theme issue |
| Q42386626 | Balancing benefits and harms in health care: technology to collect and share information about harms already exists |
| Q36077345 | Clinical trials in urology: how many patients are required to achieve statistically significant results? |
| Q83887092 | Complicity theory: an explanation for the 'coxib problem'? |
| Q42485256 | European Medicines Agency policies for clinical trials leave women unprotected. |
| Q33815886 | Evaluating ethnic differences in the prescription of NSAIDs for chronic kidney disease: a cross-sectional survey of patients in general practice |
| Q35241172 | Evaluating medical effectiveness for the california health benefits review program |
| Q38901359 | Exclusion of Elderly People from Randomized Clinical Trials of Drugs for Ischemic Heart Disease |
| Q26823455 | Generating evidence from computerized healthcare utilization databases |
| Q42412173 | Lessons from the withdrawal of rofecoxib |
| Q33894784 | Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview |
| Q37587175 | Net efficacy adjusted for risk: further developments. |
| Q41214433 | Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis |
| Q44565106 | Ototopical neomycin exposure in children with nonintact tympanic membranes |
| Q44537762 | Recommending NSAIDs and paracetamol: A survey of New Zealand physiotherapists' knowledge and behaviours |
| Q24555478 | Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis |
| Q37931231 | Special considerations with the use of intravenous immunoglobulin in older persons |
| Q38045284 | Tackling inequalities: are secondary prevention therapies for reducing post-infarction mortality used without disparities? |
| Q31119957 | The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review |
| Q38288633 | The role of tramadol in current treatment strategies for musculoskeletal pain. |
| Q37858371 | Treatment options for osteoarthritis: considerations for older adults |
Search more.